---
created: 2025-04-13
updated: 2025-04-13T10:53
id: DH*h)))_DR
specialty: immuno
specialty_id: 254
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::atezolizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::avelumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::durvalumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::atezolizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::avelumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::durvalumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::miscellaneous-pharm::akadds
  - source/ak-step1-v11::$ankingadds::fa2020::pathology
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Atezolizumab, durvalumab, and avelumab are checkpoint inhibitors that bind to **PD-L1** on tumor cells

---

# Answer
